1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 08 JUNE 2015

CNS Drug News 08 JUNE 2015

  • June 2015
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Global CINV Drugs Market On Course To Grow
Industry Brief - Biotie/FDA Reach SPA Agreement On Tozadenant Phase III PD Study
Industry Brief - Cynapsus Granted US Patent Providing Coverage For Sublingual Apomorphine
Industry Trend Analysis - Phase III Success Will Make vTv A Target
Industry Brief - Actavis Launches Namzaric
Industry Brief - Aphios Granted US Patent For AD Treatment
Industry Brief - Par Gains Appellate Court Success In Rivastigmine Patch Litigation
Industry Brief - EIP Reports First Patient Dosing In Phase II Studies Of VX-745 For AD
Industry Brief - Appeals Court Ruling Compels Continued Namenda Distribution
Industry Brief - Genzyme To Collaborate With Ablynx On MS Research Project
Industry Brief - Quebec Government To Cover Tecfidera As A First-Line Oral Treatment For MS
Industry Brief - Patient Enrolment Completed In Phase IIa Study Of RHB-104 For MS
Industry Brief - Horizon Initiates Phase III Trial Of Actimmune For FA
Industry Brief - FDA Grants ODD To MN-166 For Krabbe Disease
Industry Brief - FDA Clears Q Therapeutics' IND For Phase I/IIa Trials With Q-Cells In ALS
Industry Brief - Eisai Submits Ultra-High Dose Mecobalamin NDA In Japan For ALS
Industry Brief - Retrophin's RE-024 Receives FDA Fast Track Designation For PKAN
Industry Brief - Dr Reddy's Launches Somazina For Stroke Patients In India
Industry Brief - Edge Receives FDA ODD For EG-1962
Industry Brief - SanBio Granted Key Patent In New Treatment For Chronic Stroke
Industry Trend Analysis - More Provigil Rulings Will Dent Teva's Profits
Industry Brief - Positive Results For Latuda In First Placebo-Controlled Trial Of MDD Patients With Mixed Features
Industry Brief - Companies Gain US Guanfacine Approvals
Industry Brief - Rhodes Launches Aptensio XR In US For ADHD
Industry Brief - Neos Announces Trade Name Cotempla XR-ODT
Industry Brief - Highland Granted US Patents And NoA Covering HLD-200/HLD-100
Industry Brief - FDA Accepts Dyanavel XR NDA For Review In ADHD
Industry Brief - Cymbalta Approved In Japan For Pain Associated With Fibromyalgia
Industry Brief - FDA Grants Fast Track Designation For Intellipharmaceutics' Abuse-Deterrent Rexista Oxycodone XR
Industry Brief - ANI Gains US Oxycodone Approval
Industry Brief - PAION Initiates Further US Phase III Trial Of Remimazolam
Industry Brief - Trevena Granted Key US Composition Of Matter Patent For TRV734
Industry Trend Analysis - Probuphine On Course For FDA Approval In H116
Industry Brief - FDA Approves Expanded Indication For Qudexy XR Within The Paediatric Population
Industry Brief - Fycompa Gains Positive CHMP Opinion For PGTC Seizures
Industry Trend Analysis - Generic Contrave Will Be Worthwhile For Actavis Despite Modest Market
Industry Brief - Aloxi Gains EU Approval For CINV Prevention In Infants
Industry Brief - Ono Seeks Japanese Additional Approval For Proemend In CINV
Industry Brief - Otonomy Reports Phase IIb Top-Line Data For OTO-104 In Meniere's Disease
Industry Brief - Heron Reports Positive Results From Phase III MAGIC Study Of Sustol
Industry Brief - UCB Exercises Option To License Programme From Oncodesign Targeting Neurological Diseases
Industry Brief - BDSI Raises Funds For Bunavail Commercialisation

Table Of Contents

CNS Drug News 08 JUNE 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.